Figure 4.

Human pulmonary artery smooth muscle cells (HPASMCs) were treated using 0.01 crude drug g/ml TRQ, 50 μM SKF96365, 60 nM cysteine, and/or 200 ng/ml CX3CL1 and undergoing hypoxia (2% O₂) for 24 h. (a) Protein expression of TRPC1 was detected by immunofluorescence. (b) Relative TRPC1 was analyzed (to normal) ^∗P < 0.05 and ^∗∗P < 0.01 vs. normal group. ^#P < 0.05 and ^##P < 0.01 vs. hypoxia group. n = 3. (c) The expression of TRCP1, CX3CR1, HIF-1α, NF-κBp65, and p-NF-κBp65 was measured using western blotting. (d) The expression of TRCP1, CX3CR1, HIF-1α, NF-κBp65, and p-NF-κBp65 was analyzed from blots. ^∗P < 0.05 and ^∗∗P < 0.01 vs. normal group. ^#P < 0.05 and ^##P < 0.01 vs. hypoxia group. n = 3. (e) The level of NF-κBp65 in cell supernatant was assayed using the ELISA kit. ^∗P < 0.05 and ^∗∗P < 0.01 vs. normal group. ^#P < 0.05 and ^##P < 0.01 vs. hypoxia group. n = 3.